These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2443622)

  • 1. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy.
    Howell SB; Zimm S; Markman M; Abramson IS; Cleary S; Lucas WE; Weiss RJ
    J Clin Oncol; 1987 Oct; 5(10):1607-12. PubMed ID: 2443622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.
    Piver MS; Recio FO; Baker TR; Driscoll D
    Cancer; 1994 Mar; 73(6):1693-8. PubMed ID: 7512437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Recio FO; Piver MS; Hempling RE; Driscoll DL
    Gynecol Oncol; 1998 Mar; 68(3):267-73. PubMed ID: 9570979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
    Reichman B; Markman M; Hakes T; Hoskins W; Rubin S; Jones W; Almadrones L; Ochoa M; Chapman D; Saigo P
    J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity.
    Markman M; Howell SB; Lucas WE; Pfeifle CE; Green MR
    J Clin Oncol; 1984 Dec; 2(12):1321-6. PubMed ID: 6542584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin.
    Markman M; Cleary S; Lucas W; Weiss R; Howell SB
    Cancer Treat Rep; 1986 Jun; 70(6):755-60. PubMed ID: 2425962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
    Gladieff L; Chatelut E; Gaspard MH; Skaf R; de Forni M; Mihura J; Canal P; Bugat R
    Bull Cancer; 1999; 86(7-8):673-7. PubMed ID: 10477384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease.
    Barakat RR; Fennelly D; Pizzuto F; Venkatraman ES; Brown C; Curtin JP
    Eur J Gynaecol Oncol; 1997; 18(3):161-3. PubMed ID: 9174826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.
    Markman M; Hakes T; Reichman B; Hoskins W; Rubin S; Jones W; Almadrones L; Yordan EL; Eriksson J; Lewis JL
    J Clin Oncol; 1991 Feb; 9(2):204-10. PubMed ID: 1988569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-based chemotherapy in advanced ovarian cancer: initial experience in an Indian set-up.
    Charak BS; Agarwala S; Gopal R; Advani SH; Nadkarni KS; Pai VR; Saikia TK; Desai PB
    Indian J Cancer; 1989 Jun; 26(2):85-91. PubMed ID: 2592001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
    Malmström H; Rasmussen S; Simonsen E
    Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.